ALK and hemolytic-uremic syndrome: The baseline HUS among patients who received alectinib as their last ALK TKI was 0.754, which increased by 0.064 at 3 months representing a statistically significant and clinically meaningful increase (p = 0.048); at 6 and 12 months, HUS was maintained from baseline.